Basics Corcept Therapeutics Incorporated Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol. IPO Date: April 14, 2004 Sector: Healthcare Industry: Pharma Market Cap: $7.31B Activated in VL: True Average Daily Range Avg Daily Range: $0.28 | 2.78% Avg Daily Range (30 D): $1.13 | 1.65% Avg Daily Range (90 D): $1.27 | 1.77% Institutional Daily Volume Avg Daily Volume: .48M Avg Daily Volume (30 D): .63M Avg Daily Volume (90 D): .86M Trade Size Avg Trade Size (Sh.): 101 Avg Trade Size (Sh.) (30 D): 38 Avg Trade Size (Sh.) (90 D): 42 Institutional Trades Total Inst.Trades: 4,313 Avg Inst. Trade: $2.73M Avg Inst. Trade (30 D): $5.13M Avg Inst. Trade (90 D): $7M Avg Inst. Trade Volume: .11M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $3.76M Avg Closing Trade (30 D): $7.68M Avg Closing Trade (90 D): $13.59M Avg Closing Volume: 139.47K     News May 8, 2025 @ 5:00 PM High- and Low-Grade Serous Ovarian Cancer Market i... Source: Delveinsight Dec 11, 2024 @ 6:00 PM Alcohol Use Disorder Market Set for Remarkable Gro... Source: Delveinsight Sep 19, 2024 @ 7:36 PM Corcept Moves 6.5% Higher: Will This Strength Last... Source: Zacks Sep 3, 2024 @ 8:29 PM Corcept Shares Rise More Than 45% in Six Months: H... Source: Zacks Aug 6, 2024 @ 10:20 AM Should You Invest in the First Trust NYSE Arca Bio... Source: Zacks Investment Research Financials   TTM Q2 2025 Q1 2025 Basic EPS $1.26 $.33 $.19 Diluted EPS $1.12 $.29 $.17 Revenue $ 716.08M $ 194.43M $ 157.21M Gross Profit $ 704.42M $ 191M $ 154.81M Net Income / Loss $ 133.66M $ 35.15M $ 20.55M Operating Income / Loss $ 101.95M $ 26.68M $ 3.42M Cost of Revenue $ 11.66M $ 3.43M $ 2.4M Net Cash Flow $ -25.84M $ 12.93M $ -37.85M PE Ratio 61.88